• Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=20406486).
  
• Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=20406486).
  

PubMed=20406486; DOI=10.1186/1479-5876-8-39; PMCID=PMC2876068
Jonas Norskov Sondergaard, Ramin Nazarian, Qi Wang, De-Liang Guo, Teli Hsueh, Stephen Mok, Hooman Sazegar, Laura Eleanor MacConaill, Jordi Ginesta Barretina, Sarah M. Kehoe, Narsis Attar ...Show all 19 authors... , Erika Maria von Euw, Jonathan E. Zuckerman, Bartosz Chmielowski, Begonya Comin-Anduix, Richard C. Koya, Paul Salomon Mischel, Roger S. Lo, Antoni Ribas; Show fewer authors
Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.
J. Transl. Med. 8:39.1-39.11(2010)

PubMed=22515704; DOI=10.1186/1476-4598-11-22; PMCID=PMC3444881
Erika Maria von Euw, Mohammad Atefi, Narsis Attar, Connie Chu, Sybil Zachariah, Barry L. Burgess, Stephen Mok, Charles Ng, Deborah Jean Lee Wong, Bartosz Chmielowski, David I. Lichter ...Show all 15 authors... , Richard C. Koya, Tara A. McCannel, Elena Izmailova, Antoni Ribas; Show fewer authors
Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.
Mol. Cancer 11:22.1-22.9(2012)

PubMed=24735930; DOI=10.1186/1476-4598-13-83; PMCID=PMC4021505
Amanda Lassen, Mohammad Atefi, Lidia Robert, Deborah Jean Lee Wong, Michael Cerniglia, Begonya Comin-Anduix, Antoni Ribas;
Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.
Mol. Cancer 13:83.1-83.14(2014)

PubMed=29229836; DOI=10.1073/pnas.1712064115; PMCID=PMC5748184
Ya-Peng Su, Wei Wei, Lidia Robert, Min Xue, Jennifer Tsoi, Angel Garcia-Diaz, Blanca Homet Moreno, Jungwoo Kim, Rachel Hin-Ying Ng, Jihoon W. Lee, Richard C. Koya ...Show all 15 authors... , Begonya Comin-Anduix, Thomas G. Graeber, Antoni Ribas, James Richard Heath; Show fewer authors
Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance.
Proc. Natl. Acad. Sci. U.S.A. 114:13679-13684(2017)